Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study

AIMS/INTRODUCTION: Canagliflozin is a sodium–glucose cotransporter 2 inhibitor under development for the treatment of type 2 diabetes. Our aim was to examine its efficacy and safety as monotherapy or in combination with commonly used oral antihyperglycemic drugs in Japanese patients with type 2 diab...

Descripción completa

Detalles Bibliográficos
Autores principales: Inagaki, Nobuya, Kondo, Kazuoki, Yoshinari, Toru, Kuki, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364856/
https://www.ncbi.nlm.nih.gov/pubmed/25802729
http://dx.doi.org/10.1111/jdi.12266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364856/
https://www.ncbi.nlm.nih.gov/pubmed/25802729
http://dx.doi.org/10.1111/jdi.12266

Ejemplares similares